Clinical Trial Update: Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on neoadjuvant modified FOLFIRINOX for borderline resectable pancreatic cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Modified FOLFIRINOX (modified FOLFIRINOX)

Snippet

Sponsor: Asan Medical Center | Conditions: Pancreatic Adenocarcinoma | Phase 2 | Status: COMPLETED